Related Experiment Video

Updated: May 23, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Advances in first-line treatment for patients with HER-2+ metastatic breast cancer

Leticia De Mattos-Arruda1, Javier Cortes

  • 1Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

The Oncologist
|April 24, 2012
PubMed
Abstract

Insights

Trastuzumab plus chemotherapy is the standard first-line treatment for HER-2(+) breast cancer. New anti-HER-2 therapies are emerging, offering evolving strategies for patients with HER-2-positive metastatic breast cancer.

Area of Science:

  • Oncology
  • Medical Therapeutics
  • Breast Cancer Research

Background:

  • Prognosis for HER-2(+) breast cancer improved with anti-HER-2 therapy.
  • Trastuzumab and chemotherapy are standard first-line treatment.
  • Optimal therapeutic regimens and evolving strategies are under investigation.

Purpose of the Study:

  • To review current and emerging first-line treatment strategies for HER-2(+) metastatic breast cancer.
  • To evaluate the efficacy of different chemotherapy combinations with trastuzumab.
  • To explore novel anti-HER-2 therapies and their role in treatment.

Main Methods:

  • Literature review of clinical trials, reviews, and ongoing studies.
  • Focus on first-line treatment for HER-2(+) metastatic breast cancer.
  • Analysis of treatment regimens including chemotherapy, targeted therapy, and combination therapies.

Main Results:

  • Taxanes are common in combination with trastuzumab.
  • Other chemotherapy agents (anthracyclines, vinorelbine, gemcitabine) and triple therapies studied.
  • Aromatase inhibitors with anti-HER-2 therapies show potential but are less active than chemotherapy.
  • New anti-HER-2 therapies demonstrate activity alone and with trastuzumab.

Conclusions:

  • Trastuzumab plus chemotherapy remains the standard upfront treatment for HER-2(+) breast cancer.
  • Emerging anti-HER-2 agents may become future standards of care.
  • Continued research is vital for optimizing treatment for HER-2(+) breast cancer.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...